Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Распространенность, осведомленность и приверженность лечению артериальной гипертензии: мифы и реальность - Журнал Системные Гипертензии Том 15, №1
Распространенность, осведомленность и приверженность лечению артериальной гипертензии: мифы и реальность
Кривошапова К.Е., Цыганкова Д.П., Барбараш О.Л. Распространенность, осведомленность и приверженность лечению артериальной гипертензии: мифы и реальность. Системные гипертензии. 2018; 15 (1): 63–67. DOI: 10.26442/2075-082X_15.1.63-67
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзоре проведен анализ результатов крупных эпидемиологических исследований, направленных на оценку распространенности одного из самых грозных факторов риска сердечно-сосудистых заболеваний – артериальной гипертензии с позиции социально-экономических факторов («Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в Российской Федерации», ЭССЕ, Prospective Urban and Rural Epidemiological Study, PURE). Приводится сравнительная характеристика как показателей распространенности артериальной гипертензии, так и уровня осведомленности населения о ее наличии, приверженности лечению и контролю артериального давления среди жителей стран с различным социально-экономическим уровнем. Сделан вывод о том, что, несмотря на проведение профилактических мер, разрыв между выявлением артериальной гипертензии, последующим контролем артериального давления и приверженностью лечению в большинстве стран мира остается большим, что свидетельствует о необходимости более тщательного анализа возможных причин и разработки новейших профилактических мер.
Ключевые слова: артериальная гипертензия, распространенность, осведомленность, контроль, артериальное давление, факторы риска, первичная профилактика, вторичная профилактика.
Key words: arterial hypertension, prevalence, awareness, control, blood pressure, risk factors, primary prevention, secondary prevention.
Ключевые слова: артериальная гипертензия, распространенность, осведомленность, контроль, артериальное давление, факторы риска, первичная профилактика, вторичная профилактика.
________________________________________________
Key words: arterial hypertension, prevalence, awareness, control, blood pressure, risk factors, primary prevention, secondary prevention.
Полный текст
Список литературы
1. World Health Organization. Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization, 2009.
2. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (9623): 1513–8.
3. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
4. Nieuwlaat R, Schwalm JD, Khatib R et al. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J 2013; 34 (17): 1262–9.
5. Baker R, Camosso-Stefinovic J, Gillies C et al. Tailored interventions to overcome identified barriers to change: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2010; 3.
6. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 4 (14): 4–14. / Boitsov S.A., Balanova Yu.A., Shal'nova S.A. i dr. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovaskuliarnaia terapiia i profilaktika. 2014; 4 (14): 4–14. [in Russian]
7. Максимов С.А., Табакаев М.В., Артамонова Г.В. Интегральная оценка риска ишемической болезни сердца в эпидемиологических исследованиях (ЭССЕ-РФ в Кемеровской области). Сообщение II: социально-экономические детерминанты. Профилактич. медицина. 2016; 1 (19): 24–9. / Maksimov S.A., Tabakaev M.V., Artamonova G.V. Integral'naia otsenka riska ishemicheskoi bolezni serdtsa v epidemiologicheskikh issledovaniiakh (ESSE-RF v Kemerovskoi oblasti). Soobshchenie II: sotsial'no-ekonomicheskie determinanty. Profilaktich. meditsina. 2016; 1 (19): 24–9. [in Russian]
8. Результаты второго этапа мониторинга эпидемиологической ситуации по артериальной гипертонии в Российской Федерации (2005–2007 гг.), проведенного в рамках федеральной целевой программы «Профилактика и лечение артериальной гипертонии». Информационно-статистич. сб. М., 2008. / Rezul'taty vtorogo etapa monitoringa epidemiologicheskoi situatsii po arterial'noi gipertonii v Rossiiskoi Federatsii (2005–2007 gg.), provedennogo v ramkakh federal'noi tselevoi programmy “Profilaktika i lechenie arterial'noi gipertonii“. Informatsionno-statistich. sb. M., 2008. [in Russian]
9. Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
10. Wolf-Maier K, Cooper R, Banegas J. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363–9.
11. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиологич. журн. 2006; 4: 45–50. / Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. i dr. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiologich. zhurn. 2006; 4: 45–50. [in Russian]
12. Kearney P, Whelton M, Reynolds K et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11–9.
13. He J, Gu D, Chen J et al. Premature deaths attributable to blood pressure in China. Lancet 2009; 374 (9703): 1765–72.
14. Palafox B, McKee M, Balabanova D et al. Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries. Int J Equity Health 2016; 15 (1): 199.
15. World Bank. How we classify countries. Accessed 2011.
16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305–15.
17. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2015; 387 (10 022): 957–67.
18. Chazova IE, Zhernakova YuV, Oshchepkova EV et al. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologia 2014; 10: 4–12.
19. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med Massachusetts Med Soc 2008; 358 (15): 1547–59.
20. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the Future of Cardiovascular Disease in the United States. A Policy Statement From the American Heart Association. Circulation 2011; 123: 933–44.
21. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour. J Adv Nurs 2005; 49 (6): 616–23.
22. Ostchega Y, Dillon CF, Hughes JP et al. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55 (7): 1056–65.
23. Gee ME, Campbell NR, Gwadry-Sridhar F et al. Antihypertensive medication use, adherence, stops, and starts in Canadians with hypertension. Can J Cardiol 2012; 28 (3): 383–9.
24. Kusuma SY. Migrants’ perceptions on barriers to treatment seeking for hypertension: A qualitative study from Delhi, India. Ethnomed 2010; 44 (3): 173–6.
25. Meng X, Dong G, Wang D et al. Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities of China: the CHPSNE study. J Hypertens 2011; 7 (29): 1303–10.
26. Khatib R, Schwalm J-D, Yusuf S et al. Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies. PLoS ONE 2014; 9 (1): e84238.
27. Anthony H, Valinsky L, Inbar Z et al. Perceptions of hypertension treatment among patients with and without diabetes. BMC Fam Pract 2012; 13: 24.
28. Ford CD, Kim MJ, Dancy BL et al. Perceptions of hypertension and contributing personal and environmental factors among rural southern African, Аmerican women. Ethn Dis 2009; 19 (4): 407–13.
29. Ogedegbe G, Harrison M, Robbins L et al. Barriers and facilitators of medication adherence in hypertensive African, Аmericans: A qualitative study. Ethn Dis 2004; 14 (1): 3–12.
30. Schafheutle EI, Hassell K, Noyce PR et al. Access to medicines: Cost as an influence on the views and behaviour of patients. Health Soc Care Community 2002; 10 (3): 187–95.
31. Parker WA, Steyn NP, Levitt NS et al. Health promotion services for patients having non-comminicable diseases: Feedback from patients and health care providers in cape town, south africa. BMC Public Health 2012; 12: 503.
32. Horowitz CR, Tuzzio L, Rojas M et al. How do urban African Аmericans and Latinos View the influence of Diet on Hypertension? J Health Care Poor Underserved 2004; 15 (4): 631–44.
33. Wexler R, Elton T, Pleister A et al. Barriers to blood pressure control as reported by African American patients. J Natl Med Assoc 2009; 101 (6): 597–603.
34. Aroian KJ, Peters RM, Rudner N et al. Hypertension prevention beliefs of hispanics. J Transcult Nurs 2012; 23 (2): 134–42.
35. Greer TM. Perceived racial discrimination in clinical encounters among African American hypertensive patients. J Health Care Poor Underserved 2010; 21 (1): 251–63.
36. Murimi MW, Harpel T. Practicing preventive health: The underlying culture among low-income rural populations. J Rural Health 2010; 26 (3): 273–82.
37. Fongwa MN, Evangelista LS, Hays RD et al. Adherence treatment factors in hypertensive Аfrican Аmerican women. Vasc Health Risk Manag 2008; 4 (1): 157–66.
38. Peters DH, Garg A, Bloom G et al. Poverty and access to health care in developing countries. Ann NY Acad Sci 2008; 1136: 161–71.
39. Barnes DM, Lu JH. Mexican immigrants’ and mexican аmericans’ perceptions of hypertension. Qual Health Res 2012; 22 (12): 1685–93.
40. Pham TM, Rosenthal MP, Diamond JJ. Hypertension, cardiovascular disease, and health care dilemmas in the philadelphia vietnamese community. Fam Med 1999; 31 (9): 647–51.
41. Arrieta MI, Foreman RD, Crook ED et al. Providing continuity of care for chronic diseases in the aftermath of katrina: From field experience to policy recommendations. Dis Med Pub Health Prep 2009; 3 (3): 174–82.
42. Lim SS, Vox T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease. Lancet 2012; 380 (9859): 2224–60.
2. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (9623): 1513–8.
3. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
4. Nieuwlaat R, Schwalm JD, Khatib R et al. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J 2013; 34 (17): 1262–9.
5. Baker R, Camosso-Stefinovic J, Gillies C et al. Tailored interventions to overcome identified barriers to change: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2010; 3.
6. Boitsov S.A., Balanova Yu.A., Shal'nova S.A. i dr. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovaskuliarnaia terapiia i profilaktika. 2014; 4 (14): 4–14. [in Russian]
7. Maksimov S.A., Tabakaev M.V., Artamonova G.V. Integral'naia otsenka riska ishemicheskoi bolezni serdtsa v epidemiologicheskikh issledovaniiakh (ESSE-RF v Kemerovskoi oblasti). Soobshchenie II: sotsial'no-ekonomicheskie determinanty. Profilaktich. meditsina. 2016; 1 (19): 24–9. [in Russian]
8. Rezul'taty vtorogo etapa monitoringa epidemiologicheskoi situatsii po arterial'noi gipertonii v Rossiiskoi Federatsii (2005–2007 gg.), provedennogo v ramkakh federal'noi tselevoi programmy “Profilaktika i lechenie arterial'noi gipertonii“. Informatsionno-statistich. sb. M., 2008. [in Russian]
9. Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
10. Wolf-Maier K, Cooper R, Banegas J. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363–9.
11. Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. i dr. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiologich. zhurn. 2006; 4: 45–50. [in Russian]
12. Kearney P, Whelton M, Reynolds K et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11–9.
13. He J, Gu D, Chen J et al. Premature deaths attributable to blood pressure in China. Lancet 2009; 374 (9703): 1765–72.
14. Palafox B, McKee M, Balabanova D et al. Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries. Int J Equity Health 2016; 15 (1): 199.
15. World Bank. How we classify countries. Accessed 2011.
16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305–15.
17. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2015; 387 (10 022): 957–67.
18. Chazova IE, Zhernakova YuV, Oshchepkova EV et al. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologia 2014; 10: 4–12.
19. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med Massachusetts Med Soc 2008; 358 (15): 1547–59.
20. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the Future of Cardiovascular Disease in the United States. A Policy Statement From the American Heart Association. Circulation 2011; 123: 933–44.
21. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour. J Adv Nurs 2005; 49 (6): 616–23.
22. Ostchega Y, Dillon CF, Hughes JP et al. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55 (7): 1056–65.
23. Gee ME, Campbell NR, Gwadry-Sridhar F et al. Antihypertensive medication use, adherence, stops, and starts in Canadians with hypertension. Can J Cardiol 2012; 28 (3): 383–9.
24. Kusuma SY. Migrants’ perceptions on barriers to treatment seeking for hypertension: A qualitative study from Delhi, India. Ethnomed 2010; 44 (3): 173–6.
25. Meng X, Dong G, Wang D et al. Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities of China: the CHPSNE study. J Hypertens 2011; 7 (29): 1303–10.
26. Khatib R, Schwalm J-D, Yusuf S et al. Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies. PLoS ONE 2014; 9 (1): e84238.
27. Anthony H, Valinsky L, Inbar Z et al. Perceptions of hypertension treatment among patients with and without diabetes. BMC Fam Pract 2012; 13: 24.
28. Ford CD, Kim MJ, Dancy BL et al. Perceptions of hypertension and contributing personal and environmental factors among rural southern African, Аmerican women. Ethn Dis 2009; 19 (4): 407–13.
29. Ogedegbe G, Harrison M, Robbins L et al. Barriers and facilitators of medication adherence in hypertensive African, Аmericans: A qualitative study. Ethn Dis 2004; 14 (1): 3–12.
30. Schafheutle EI, Hassell K, Noyce PR et al. Access to medicines: Cost as an influence on the views and behaviour of patients. Health Soc Care Community 2002; 10 (3): 187–95.
31. Parker WA, Steyn NP, Levitt NS et al. Health promotion services for patients having non-comminicable diseases: Feedback from patients and health care providers in cape town, south africa. BMC Public Health 2012; 12: 503.
32. Horowitz CR, Tuzzio L, Rojas M et al. How do urban African Аmericans and Latinos View the influence of Diet on Hypertension? J Health Care Poor Underserved 2004; 15 (4): 631–44.
33. Wexler R, Elton T, Pleister A et al. Barriers to blood pressure control as reported by African American patients. J Natl Med Assoc 2009; 101 (6): 597–603.
34. Aroian KJ, Peters RM, Rudner N et al. Hypertension prevention beliefs of hispanics. J Transcult Nurs 2012; 23 (2): 134–42.
35. Greer TM. Perceived racial discrimination in clinical encounters among African American hypertensive patients. J Health Care Poor Underserved 2010; 21 (1): 251–63.
36. Murimi MW, Harpel T. Practicing preventive health: The underlying culture among low-income rural populations. J Rural Health 2010; 26 (3): 273–82.
37. Fongwa MN, Evangelista LS, Hays RD et al. Adherence treatment factors in hypertensive Аfrican Аmerican women. Vasc Health Risk Manag 2008; 4 (1): 157–66.
38. Peters DH, Garg A, Bloom G et al. Poverty and access to health care in developing countries. Ann NY Acad Sci 2008; 1136: 161–71.
39. Barnes DM, Lu JH. Mexican immigrants’ and mexican аmericans’ perceptions of hypertension. Qual Health Res 2012; 22 (12): 1685–93.
40. Pham TM, Rosenthal MP, Diamond JJ. Hypertension, cardiovascular disease, and health care dilemmas in the philadelphia vietnamese community. Fam Med 1999; 31 (9): 647–51.
41. Arrieta MI, Foreman RD, Crook ED et al. Providing continuity of care for chronic diseases in the aftermath of katrina: From field experience to policy recommendations. Dis Med Pub Health Prep 2009; 3 (3): 174–82.
42. Lim SS, Vox T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease. Lancet 2012; 380 (9859): 2224–60.
2. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (9623): 1513–8.
3. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
4. Nieuwlaat R, Schwalm JD, Khatib R et al. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J 2013; 34 (17): 1262–9.
5. Baker R, Camosso-Stefinovic J, Gillies C et al. Tailored interventions to overcome identified barriers to change: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2010; 3.
6. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 4 (14): 4–14. / Boitsov S.A., Balanova Yu.A., Shal'nova S.A. i dr. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovaskuliarnaia terapiia i profilaktika. 2014; 4 (14): 4–14. [in Russian]
7. Максимов С.А., Табакаев М.В., Артамонова Г.В. Интегральная оценка риска ишемической болезни сердца в эпидемиологических исследованиях (ЭССЕ-РФ в Кемеровской области). Сообщение II: социально-экономические детерминанты. Профилактич. медицина. 2016; 1 (19): 24–9. / Maksimov S.A., Tabakaev M.V., Artamonova G.V. Integral'naia otsenka riska ishemicheskoi bolezni serdtsa v epidemiologicheskikh issledovaniiakh (ESSE-RF v Kemerovskoi oblasti). Soobshchenie II: sotsial'no-ekonomicheskie determinanty. Profilaktich. meditsina. 2016; 1 (19): 24–9. [in Russian]
8. Результаты второго этапа мониторинга эпидемиологической ситуации по артериальной гипертонии в Российской Федерации (2005–2007 гг.), проведенного в рамках федеральной целевой программы «Профилактика и лечение артериальной гипертонии». Информационно-статистич. сб. М., 2008. / Rezul'taty vtorogo etapa monitoringa epidemiologicheskoi situatsii po arterial'noi gipertonii v Rossiiskoi Federatsii (2005–2007 gg.), provedennogo v ramkakh federal'noi tselevoi programmy “Profilaktika i lechenie arterial'noi gipertonii“. Informatsionno-statistich. sb. M., 2008. [in Russian]
9. Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
10. Wolf-Maier K, Cooper R, Banegas J. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363–9.
11. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиологич. журн. 2006; 4: 45–50. / Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. i dr. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiologich. zhurn. 2006; 4: 45–50. [in Russian]
12. Kearney P, Whelton M, Reynolds K et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11–9.
13. He J, Gu D, Chen J et al. Premature deaths attributable to blood pressure in China. Lancet 2009; 374 (9703): 1765–72.
14. Palafox B, McKee M, Balabanova D et al. Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries. Int J Equity Health 2016; 15 (1): 199.
15. World Bank. How we classify countries. Accessed 2011.
16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305–15.
17. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2015; 387 (10 022): 957–67.
18. Chazova IE, Zhernakova YuV, Oshchepkova EV et al. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologia 2014; 10: 4–12.
19. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med Massachusetts Med Soc 2008; 358 (15): 1547–59.
20. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the Future of Cardiovascular Disease in the United States. A Policy Statement From the American Heart Association. Circulation 2011; 123: 933–44.
21. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour. J Adv Nurs 2005; 49 (6): 616–23.
22. Ostchega Y, Dillon CF, Hughes JP et al. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55 (7): 1056–65.
23. Gee ME, Campbell NR, Gwadry-Sridhar F et al. Antihypertensive medication use, adherence, stops, and starts in Canadians with hypertension. Can J Cardiol 2012; 28 (3): 383–9.
24. Kusuma SY. Migrants’ perceptions on barriers to treatment seeking for hypertension: A qualitative study from Delhi, India. Ethnomed 2010; 44 (3): 173–6.
25. Meng X, Dong G, Wang D et al. Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities of China: the CHPSNE study. J Hypertens 2011; 7 (29): 1303–10.
26. Khatib R, Schwalm J-D, Yusuf S et al. Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies. PLoS ONE 2014; 9 (1): e84238.
27. Anthony H, Valinsky L, Inbar Z et al. Perceptions of hypertension treatment among patients with and without diabetes. BMC Fam Pract 2012; 13: 24.
28. Ford CD, Kim MJ, Dancy BL et al. Perceptions of hypertension and contributing personal and environmental factors among rural southern African, Аmerican women. Ethn Dis 2009; 19 (4): 407–13.
29. Ogedegbe G, Harrison M, Robbins L et al. Barriers and facilitators of medication adherence in hypertensive African, Аmericans: A qualitative study. Ethn Dis 2004; 14 (1): 3–12.
30. Schafheutle EI, Hassell K, Noyce PR et al. Access to medicines: Cost as an influence on the views and behaviour of patients. Health Soc Care Community 2002; 10 (3): 187–95.
31. Parker WA, Steyn NP, Levitt NS et al. Health promotion services for patients having non-comminicable diseases: Feedback from patients and health care providers in cape town, south africa. BMC Public Health 2012; 12: 503.
32. Horowitz CR, Tuzzio L, Rojas M et al. How do urban African Аmericans and Latinos View the influence of Diet on Hypertension? J Health Care Poor Underserved 2004; 15 (4): 631–44.
33. Wexler R, Elton T, Pleister A et al. Barriers to blood pressure control as reported by African American patients. J Natl Med Assoc 2009; 101 (6): 597–603.
34. Aroian KJ, Peters RM, Rudner N et al. Hypertension prevention beliefs of hispanics. J Transcult Nurs 2012; 23 (2): 134–42.
35. Greer TM. Perceived racial discrimination in clinical encounters among African American hypertensive patients. J Health Care Poor Underserved 2010; 21 (1): 251–63.
36. Murimi MW, Harpel T. Practicing preventive health: The underlying culture among low-income rural populations. J Rural Health 2010; 26 (3): 273–82.
37. Fongwa MN, Evangelista LS, Hays RD et al. Adherence treatment factors in hypertensive Аfrican Аmerican women. Vasc Health Risk Manag 2008; 4 (1): 157–66.
38. Peters DH, Garg A, Bloom G et al. Poverty and access to health care in developing countries. Ann NY Acad Sci 2008; 1136: 161–71.
39. Barnes DM, Lu JH. Mexican immigrants’ and mexican аmericans’ perceptions of hypertension. Qual Health Res 2012; 22 (12): 1685–93.
40. Pham TM, Rosenthal MP, Diamond JJ. Hypertension, cardiovascular disease, and health care dilemmas in the philadelphia vietnamese community. Fam Med 1999; 31 (9): 647–51.
41. Arrieta MI, Foreman RD, Crook ED et al. Providing continuity of care for chronic diseases in the aftermath of katrina: From field experience to policy recommendations. Dis Med Pub Health Prep 2009; 3 (3): 174–82.
42. Lim SS, Vox T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease. Lancet 2012; 380 (9859): 2224–60.
________________________________________________
2. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (9623): 1513–8.
3. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68.
4. Nieuwlaat R, Schwalm JD, Khatib R et al. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J 2013; 34 (17): 1262–9.
5. Baker R, Camosso-Stefinovic J, Gillies C et al. Tailored interventions to overcome identified barriers to change: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2010; 3.
6. Boitsov S.A., Balanova Yu.A., Shal'nova S.A. i dr. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovaskuliarnaia terapiia i profilaktika. 2014; 4 (14): 4–14. [in Russian]
7. Maksimov S.A., Tabakaev M.V., Artamonova G.V. Integral'naia otsenka riska ishemicheskoi bolezni serdtsa v epidemiologicheskikh issledovaniiakh (ESSE-RF v Kemerovskoi oblasti). Soobshchenie II: sotsial'no-ekonomicheskie determinanty. Profilaktich. meditsina. 2016; 1 (19): 24–9. [in Russian]
8. Rezul'taty vtorogo etapa monitoringa epidemiologicheskoi situatsii po arterial'noi gipertonii v Rossiiskoi Federatsii (2005–2007 gg.), provedennogo v ramkakh federal'noi tselevoi programmy “Profilaktika i lechenie arterial'noi gipertonii“. Informatsionno-statistich. sb. M., 2008. [in Russian]
9. Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
10. Wolf-Maier K, Cooper R, Banegas J. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363–9.
11. Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. i dr. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiologich. zhurn. 2006; 4: 45–50. [in Russian]
12. Kearney P, Whelton M, Reynolds K et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11–9.
13. He J, Gu D, Chen J et al. Premature deaths attributable to blood pressure in China. Lancet 2009; 374 (9703): 1765–72.
14. Palafox B, McKee M, Balabanova D et al. Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries. Int J Equity Health 2016; 15 (1): 199.
15. World Bank. How we classify countries. Accessed 2011.
16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305–15.
17. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2015; 387 (10 022): 957–67.
18. Chazova IE, Zhernakova YuV, Oshchepkova EV et al. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologia 2014; 10: 4–12.
19. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med Massachusetts Med Soc 2008; 358 (15): 1547–59.
20. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the Future of Cardiovascular Disease in the United States. A Policy Statement From the American Heart Association. Circulation 2011; 123: 933–44.
21. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour. J Adv Nurs 2005; 49 (6): 616–23.
22. Ostchega Y, Dillon CF, Hughes JP et al. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55 (7): 1056–65.
23. Gee ME, Campbell NR, Gwadry-Sridhar F et al. Antihypertensive medication use, adherence, stops, and starts in Canadians with hypertension. Can J Cardiol 2012; 28 (3): 383–9.
24. Kusuma SY. Migrants’ perceptions on barriers to treatment seeking for hypertension: A qualitative study from Delhi, India. Ethnomed 2010; 44 (3): 173–6.
25. Meng X, Dong G, Wang D et al. Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities of China: the CHPSNE study. J Hypertens 2011; 7 (29): 1303–10.
26. Khatib R, Schwalm J-D, Yusuf S et al. Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies. PLoS ONE 2014; 9 (1): e84238.
27. Anthony H, Valinsky L, Inbar Z et al. Perceptions of hypertension treatment among patients with and without diabetes. BMC Fam Pract 2012; 13: 24.
28. Ford CD, Kim MJ, Dancy BL et al. Perceptions of hypertension and contributing personal and environmental factors among rural southern African, Аmerican women. Ethn Dis 2009; 19 (4): 407–13.
29. Ogedegbe G, Harrison M, Robbins L et al. Barriers and facilitators of medication adherence in hypertensive African, Аmericans: A qualitative study. Ethn Dis 2004; 14 (1): 3–12.
30. Schafheutle EI, Hassell K, Noyce PR et al. Access to medicines: Cost as an influence on the views and behaviour of patients. Health Soc Care Community 2002; 10 (3): 187–95.
31. Parker WA, Steyn NP, Levitt NS et al. Health promotion services for patients having non-comminicable diseases: Feedback from patients and health care providers in cape town, south africa. BMC Public Health 2012; 12: 503.
32. Horowitz CR, Tuzzio L, Rojas M et al. How do urban African Аmericans and Latinos View the influence of Diet on Hypertension? J Health Care Poor Underserved 2004; 15 (4): 631–44.
33. Wexler R, Elton T, Pleister A et al. Barriers to blood pressure control as reported by African American patients. J Natl Med Assoc 2009; 101 (6): 597–603.
34. Aroian KJ, Peters RM, Rudner N et al. Hypertension prevention beliefs of hispanics. J Transcult Nurs 2012; 23 (2): 134–42.
35. Greer TM. Perceived racial discrimination in clinical encounters among African American hypertensive patients. J Health Care Poor Underserved 2010; 21 (1): 251–63.
36. Murimi MW, Harpel T. Practicing preventive health: The underlying culture among low-income rural populations. J Rural Health 2010; 26 (3): 273–82.
37. Fongwa MN, Evangelista LS, Hays RD et al. Adherence treatment factors in hypertensive Аfrican Аmerican women. Vasc Health Risk Manag 2008; 4 (1): 157–66.
38. Peters DH, Garg A, Bloom G et al. Poverty and access to health care in developing countries. Ann NY Acad Sci 2008; 1136: 161–71.
39. Barnes DM, Lu JH. Mexican immigrants’ and mexican аmericans’ perceptions of hypertension. Qual Health Res 2012; 22 (12): 1685–93.
40. Pham TM, Rosenthal MP, Diamond JJ. Hypertension, cardiovascular disease, and health care dilemmas in the philadelphia vietnamese community. Fam Med 1999; 31 (9): 647–51.
41. Arrieta MI, Foreman RD, Crook ED et al. Providing continuity of care for chronic diseases in the aftermath of katrina: From field experience to policy recommendations. Dis Med Pub Health Prep 2009; 3 (3): 174–82.
42. Lim SS, Vox T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease. Lancet 2012; 380 (9859): 2224–60.
Авторы
К.Е.Кривошапова*1, Д.П.Цыганкова1,2, О.Л.Барбараш1,2
1 ФГБНУ «НИИ комплексных проблем сердечно-сосудистых заболеваний». 650002, Россия, Кемерово, Сосновый бульвар, д. 6;
2 ФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава России. 650029, Россия, Кемерово, ул. Ворошилова, д. 22а
*ya.kristi89@yandex.ru
1 Research Institute for Complex Issues of Cardiovascular Disease. 650002, Russian Federation, Kemerovo, Sosnovyi bul'var, d. 6;
2 Kemerovo State Medical University of Ministry of Health of the Russian Federation. 650029, Russian Federation, Kemerovo, ul. Voroshilova, d. 22a
*ya.kristi89@yandex.ru
1 ФГБНУ «НИИ комплексных проблем сердечно-сосудистых заболеваний». 650002, Россия, Кемерово, Сосновый бульвар, д. 6;
2 ФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава России. 650029, Россия, Кемерово, ул. Ворошилова, д. 22а
*ya.kristi89@yandex.ru
________________________________________________
1 Research Institute for Complex Issues of Cardiovascular Disease. 650002, Russian Federation, Kemerovo, Sosnovyi bul'var, d. 6;
2 Kemerovo State Medical University of Ministry of Health of the Russian Federation. 650029, Russian Federation, Kemerovo, ul. Voroshilova, d. 22a
*ya.kristi89@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.